Triple-negative breast cancer: role of specific chemotherapy agents.

@article{Isakoff2010TriplenegativeBC,
  title={Triple-negative breast cancer: role of specific chemotherapy agents.},
  author={Steven Jay Isakoff},
  journal={Cancer journal},
  year={2010},
  volume={16 1},
  pages={53-61}
}
Cytotoxic chemotherapy remains the mainstay of treatment for triple-negative breast cancer (TNBC) despite the promise of new targeted and biologic agents. Many studies have shown significant benefit of chemotherapy in the neoadjuvant, adjuvant, and metastatic treatment of TNBC. Neoadjuvant chemotherapy studies have consistently reported higher response rates in TNBC than non-TNBC, and pathologic complete response has been shown to predict improved long-term outcomes for TNBC. Although the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 84 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 77 references

Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer

  • JE Garber, A Richardson, LN Harris
  • San Antonio Breast Cancer Symposium,
  • 2006
Highly Influential
2 Excerpts

Similar Papers

Loading similar papers…